PAS-25-205 SHINE R01 eligibility Guide
Updated 4 official sources
Quick Answer: PAS-25-205 is an NIH R01 for selected nonmalignant hematology research areas under the SHINE program.
Full answer and how we checked it
It is clinical trial not allowed and should be used only when the project fits the current topic list and institute mission. The October 5, 2026 new R01 date has passed. Under PAS-25-205 (opens in a new tab), the next dates are November 5, 2026 for renewals and resubmissions and February 5, 2027 for new applications.
Who this is for: Hematology investigators, NIDDK, NHLBI, and NIA research teams, sponsored-research offices, and basic or early translational scientists deciding whether a nonmalignant hematology R01 fits SHINE.
Data note: This guide uses NIH PAS-25-205, SHINE topic notices linked from NIH, Grants.gov listing 357004, NIH standard due-date guidance, and Grantsights award-data signals checked on June 2, 2026.
In this guide
- June 2026 Source Check
- 6 PAS-25-205 Eligibility Stop Checks
- 5 Funding, Timing, and Mechanism Rules
- 5 Route Choices Before Drafting
- What NIH Doesn't Tell You
- 7 Evidence Assets That Make This R01 Stronger
- 21-Day SHINE Routing Plan
- 6 Reviewer-Risk Signals to Fix
- 7 Source-Backed Signals From PAS-25-205
- 5 Applicant Types and Best Next Move
- 7 Route Checks Added May 26, 2026
- Sources
PAS-25-205 is a focused hematology R01, not a general blood-disease catchall. According to NIH PAS-25-205 (opens in a new tab), SHINE supports selected areas of basic and early translational nonmalignant hematology research relevant to NIDDK, NHLBI, and NIA.
In some R01 routing decisions, the science is strong but the program fit is thin. SHINE is one of those routes where the first question is not "is this hematology?" The first question is whether the project fits the current SHINE topic set and the participating institute missions.
Use this guide with the live NIH SHINE R01 program record. Then compare NIH grants complete guide, NIH R01 R21 R03 K awards comparison, best NIH grants for researchers, what is a NOFO, and the Grantsights grant database.
June 2026 Source Check
As of June 2, 2026, PAS-25-205 remains active. NIH lists standard R01 dates through October 5, 2027 and an expiration date of January 7, 2028. The June 5 and October 5, 2026 new-application dates have passed. The next new-application date is February 5, 2027 by 5 p.m. local time, and the next renewal and resubmission date is November 5, 2026.
The March 31, 2025 NIH source update still matters. NIH tells applicants to reread the full opportunity and adjust applications. The current SHINE screen should verify nonmalignant hematology focus, active topic fit, NIDDK, NHLBI, or NIA mission fit, no clinical trial, R01 readiness, and whether an older SHINE topic has already reached its last accepted cycle.
Get research funding calls by email
About once a week, we email open research funding calls with a real deadline, from federal agencies such as NIH and NSF, picked for research institutions. One click to unsubscribe.
No spam. Unsubscribe anytime.
6 PAS-25-205 Eligibility Stop Checks
6 stop checks decide whether SHINE fits before a full R01 is drafted. The project should be nonmalignant hematology, within a current SHINE topic, non-trial, and strong enough for R01 peer review.
| Stop check | Strong R01 signal | Red flag |
|---|---|---|
| Hematology fit | Nonmalignant blood or marrow biology is central | Cancer-focused hematology dominates |
| Topic fit | Project matches a current SHINE topic notice | Topic is outside the active set |
| Institute fit | NIDDK, NHLBI, or NIA mission match is clear | No participating institute match |
| Trial status | No NIH-defined clinical trial | Human intervention test is planned |
| Mechanism scale | R01 scope and team capacity are credible | Pilot work should come first |
| Field value | Study addresses a defined gap | Broad discovery without route fit |
Don't assume that any hematology project belongs here. The route is stronger when the application can quote the current topic area, explain the institute fit, and show why an R01 is earned.
5 Funding, Timing, and Mechanism Rules
5 public rules should be visible before the aims page. According to NIH, PAS-25-205 is an R01 clinical trial not allowed opportunity. The last new-application date is October 5, 2027, and the last renewal and resubmission date is November 5, 2027.
| Rule | Source-backed read |
|---|---|
| Funding number | PAS-25-205 |
| Mechanism | R01 research project grant |
| Clinical trial status | Not allowed |
| Topic model | Current SHINE topics are listed and updated by NIH notices |
| Next new R01 due date | February 5, 2027 (October 5, 2026 has passed) |
| Next renewal or resubmission date | November 5, 2026 |
| Last new R01 date | October 5, 2027 |
| Expiration date | January 7, 2028 |
According to NIH, current supported topics include metabolic modulators of hematopoiesis, stem cell niche remodeling, erythrocyte maturation, hematopoietic response to stress, and bone marrow microenvironment modeling.
5 Route Choices Before Drafting
5 route choices matter because a project can be good hematology science and still belong somewhere else.
| Route | Better first read when... | Why |
|---|---|---|
| PAS-25-205 SHINE R01 | Nonmalignant hematology question fits a current SHINE topic | Program fit is strong |
| Parent R01 | Hematology topic is strong but not in SHINE scope | Broader route may fit |
| R21 or pilot route | Data are early or feasibility is thin | R01 may be premature |
| Clinical-trial route | Study assigns intervention to measure outcome | SHINE bars trials |
| Disease-specific NOFO | Topic is better aligned to another institute path | Better review fit |
The best bet is to write the topic-fit sentence first. If the team cannot name the SHINE topic and why it fits, avoid forcing the application into this route.
What NIH Doesn't Tell You
4 hidden readiness questions decide whether PAS-25-205 is worth the effort. NIH lists the rules, but it does not decide whether your project is persuasive under this program.
First, NIH does not make all hematology research SHINE research. Malignant hematology, clinical trials, and disease projects outside the current topic set can be better elsewhere.
Second, NIH does not make topic fit equal review strength. Reviewers still need a clear gap, strong methods, sample or model rationale, and a credible team.
Third, NIH does not make R01 scale automatic. If the project needs model validation, assay proof, or early data before a full R01, use a smaller route first.
Fourth, NIH does not make institute fit obvious. The application should explain whether the work is closest to NIDDK, NHLBI, NIA, or an intersecting mission area.
7 Evidence Assets That Make This R01 Stronger
7 evidence assets make a SHINE application easier to defend. The strongest applications show field need, topic fit, and R01 readiness together.
First, identify the exact nonmalignant hematology gap. According to NIH, SHINE topics can change over time, so the application should connect to the active list rather than rely on general relevance.
Second, describe why the model or system is appropriate. Bone marrow microenvironment work, erythrocyte maturation, stress hematopoiesis, and metabolism questions need methods that match the biology.
Third, show why the project is not a clinical trial. If human participants are involved, the protocol should be observational or mechanistic without an NIH-defined trial.
Fourth, prove the preliminary data are enough for R01 scope. SHINE is an R01. Reviewers can accept risk, but they won't accept an underbuilt plan.
Fifth, name the institute fit. According to NIH, NIDDK, NHLBI, and NIA participate, and each has different mission signals. The application should not leave assignment to chance.
Sixth, add a field-need paragraph. For example, a university team studying bone marrow niche changes after conditioning for nonmalignant disease could explain the workshop-derived gap, model limits, and next scientific step.
Seventh, show what the R01 will change. The result should not be "more biology." It should be a clearer disease mechanism, model, pathway, target, or research tool for nonmalignant hematology.
21-Day SHINE Routing Plan
21 days is enough to decide whether the team should draft. Days 1 through 3 should confirm PAS-25-205 status, the target receipt date, and clinical-trial-not-allowed status.
Days 4 through 7 should map the project to current SHINE topics and participating institute missions.
Days 8 through 12 should test R01 readiness: model, data, team, feasibility, and field value.
Days 13 through 16 should compare alternatives, including parent R01, R21, pilot funding, and disease-specific NOFOs.
Days 17 through 21 should prepare the NIH routing memo, including topic fit, institute assignment, trial status, and budget questions.
6 Reviewer-Risk Signals to Fix
6 risk signals should be fixed before submission. First, the application should not read like broad hematology science with a SHINE label.
Second, the topic fit should be explicit in the opening page.
Third, the trial status should be clear. Clinical trials are not allowed.
Fourth, the project should not depend on models or assays that are not ready for R01-scale work.
Fifth, the field-value argument should be concrete. Avoid vague claims that the work will help hematology generally.
Sixth, the team should contact program staff if topic or institute fit is uncertain.
7 Source-Backed Signals From PAS-25-205
7 signals from NIH should shape this page and the applicant's routing memo. The first is that PAS-25-205 is an R01, so the project needs enough evidence, team capacity, and study design strength for full R01 review.
The second is clinical-trial-not-allowed status. Any protocol that assigns an intervention to evaluate a health outcome needs a different route. If human participants are included, the application should explain why the work is not an NIH-defined clinical trial.
The third is nonmalignant hematology focus. A project can involve blood biology and still miss SHINE if cancer biology or another disease route dominates the aims.
The fourth signal is topic currency. NIH ties SHINE to current topic areas and notices. A PI should confirm the topic set close to the submission date rather than rely on last year's routing note.
The fifth signal is institute fit. NIDDK, NHLBI, and NIA each bring different mission priorities. The first page should name the closest fit and why.
The sixth signal is R01 readiness. This is not a planning route. If the model, assay, sample access, or preliminary evidence is thin, a smaller mechanism can be a better first move.
The seventh signal is field value. Reviewers need to see what the project changes for nonmalignant hematology, not only that the biology is interesting.
5 Applicant Types and Best Next Move
5 applicant types commonly ask about PAS-25-205, and each should make a different route decision.
| Applicant type | Best next move | Why |
|---|---|---|
| Nonmalignant hematology PI | Map project to current SHINE topic | Topic fit decides route |
| Clinical trial team | Use another route | SHINE bars trials |
| Early model-development team | Compare R21 or pilot | R01 may be early |
| Institute-uncertain team | Ask program staff | Assignment matters |
| Sponsored-project office | Check trial status and deadline | Technical routing can block |
The best answer is: use PAS-25-205 when the project is nonmalignant hematology, fits a current SHINE topic, is not a clinical trial, and is ready for R01 peer review.
7 Route Checks Added May 26, 2026
Checked on May 26, 2026 against PAS-25-205 (opens in a new tab), the Grants.gov listing (opens in a new tab), Grants.gov (opens in a new tab), and USASpending.gov (opens in a new tab).
| Check | What to confirm |
|---|---|
| Eligibility | Confirm the applicant, institution, and route rules for PAS-25-205 SHINE R01 eligibility. |
| Source status | Verify the official listing, notices, due date, and expiration status. |
| Budget | Check award size, cost limits, match, or budget logic when the source provides it. |
| Evidence | Name the data, preliminary work, partner role, or implementation proof needed. |
| Bad fit | Stop if the project belongs in a nearby NIH or federal route. |
| Review criteria | Tie the first page to significance, approach, team, environment, and source-specific criteria. |
| Next action | Decide whether to draft, ask a program contact, or redirect. |
Final public checklist
- Recheck the current SHINE topic list and the March 31, 2025 update before routing.
- Confirm the work is nonmalignant hematology and not a clinical trial.
- Compare SHINE with parent R01, R21, pilot, and institute-specific routes.
- Confirm whether R01 is the right route or whether a nearby program fits better.
- Check budget, partner, match, or data-readiness constraints.
Sources
3 sources anchor this guide: the NIH SHINE R01 NOFO, the federal listing, and the Grantsights public database record.
- NIH PAS-25-205 SHINE R01 NOFO: grants.nih.gov (opens in a new tab)
- Grants.gov listing 357004: grants.gov (opens in a new tab)
- Grantsights program record: NIH SHINE R01
Next steps
Where to go next
These next pages help you move from research into a specific grant choice.
Open the SHINE record
Check PAS-25-205, June 2026 timing, topic fit, institute fit, and no-trial status.
Compare R01 readiness
Use when the project may need R21, pilot, parent R01, or institute-specific routing.
Review NIH mechanics
Check standard due dates, assignment, review, and submission setup.
Find grants that fit you
Free eligibility check: answer 9 questions and see ranked matches with deadlines and fit reasons.
Frequently Asked Questions
What does PAS-25-205 fund?
NIH says SHINE supports high-quality nonmalignant hematology research in areas relevant to NIDDK, NHLBI, and NIA missions.
Are clinical trials allowed?
No. PAS-25-205 is clinical trial not allowed.
Does SHINE cover all hematology research?
No. NIH lists specific current SHINE topic areas and updates the route through notices.
What is the deadline?
The last application dates in PAS-25-205 are October 5, 2027 for new applications and November 5, 2027 for renewals and resubmissions. Grants.gov shows a January 6, 2028 close date and NIH lists a January 7, 2028 expiration, but those aren't extra submission dates.
Who should skip this route?
Skip it if the project is malignant hematology, a clinical trial, or outside the current SHINE topic areas.
Last updated October 10, 2026. Corrected October 10, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.
Related Guides
Complete Guide
NIH Grants 2026: R01, K Awards, R21, R35, SBIR
Compare NIH R01, K awards, R21, R03, R35, SBIR/STTR, success rates, deadlines, and program pages before choosing a route.
Latin America health disparities R01 eligibility Guide
NIMHD ended PAR-25-342 early on June 3, 2026. What the Latin America R01 covered, 8 fit checks, and where to look for current NIMHD funding.
NIH BRG R01 Guide 2026: Eligibility
NIH BRG R01 guide for 2026: eligibility, $500K direct-cost cap, clinical-trial status, team fit, R01 route checks, and fit.
NIH Clinical Center U01 Eligibility Guide
NIH Clinical Center U01 guide: 8 checks for PAR-26-116, intramural collaboration, Clinical Center use, $500K direct-cost cap, and LOS prep.
NIH Emergency Competitive Revision Guide
PA-24-201 guide: NIH emergency competitive revision eligibility, active parent award rule, Emergency NOSI requirement, disaster basis, and route checks.
NIH K24 Midcareer Investigator Award Guide
NIH K24 midcareer investigator award eligibility guide for PA-24-188, 25% to 50% effort, mentoring proof, trial limits, and route choice.